Glufosfamide as a new oxazaphosphorine anticancer agent

Anti-Cancer Drugs

Volumn 22, Issue 6, 2011, Pages 488-493

  Mazur, Lidia ^a   Opydo Chanek, Małgorzata ^a   Stojak, Marta ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

D glucose isophosphoramide mustard; alkylating drugs; cancer therapy; D 19575; glufosfamide; new therapeutic strategy; novel anticancer agent; oxazaphosphorines; preclinical studies and clinical trials

Indexed keywords

ALDOPHOSPHAMIDE PERHYDROTHIAZINE; ALDOPHOSPHAMIDE TIAZOLIDINE; ANTINEOPLASTIC AGENT; BROMOFOSFAMIDE; CASPASE 3; CASPASE 8; CASPASE 9; CELL PROTEIN; GEMCITABINE; GLUCOSE TRANSPORTER; GLUFOSFAMIDE; IFOSFAMIDE; OXAZAPHOSPHORINE; PHLORENTIN; PHLORIZIN; PLATINUM COMPLEX; PROTEIN BCL 2; SODIUM GLUCOSE COTRANSPORTER; UNCLASSIFIED DRUG;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HEAD AND NECK CARCINOMA; HEMORRHAGIC CYSTITIS; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LUNG NON SMALL CELL CANCER; METABOLIC ACIDOSIS; METASTASIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; URINARY TRACT DISEASE; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; GLUCOSE; HUMANS; IFOSFAMIDE; NEOPLASMS; PHOSPHORAMIDE MUSTARDS;

EID: 79958280117     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328345e1e0     Document Type: Review

References (58)

1. Brock N, Pohl J, Stekar J. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. J Cancer Res Clin Oncol 1981; 100:311-320. (Pubitemid 11051539)
2. Body AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmakcokinet 2000; 38:291-304. (Pubitemid 30229466)
3. Zhang J, Tian Q, Chan SY, Duan W, Zhou S. Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist Updat 2005; 8:271-297. (Pubitemid 41677712)
4. Zhang J, Tian Q, Chan SY, Li SC, Zhou S, Duan W, et al. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 2005; 37:611-703. (Pubitemid 43071142)
5. Zhang J, Tian Q, Zhu YZ, Xu AL, Zhou SF. Reversal of resistance to oxazaphosphorines. Curr Cancer Drug Targets 2006; 6:385-407. (Pubitemid 44042882)
6. Misiura K. Ifosfamide. Metabolic studies, new therapeutic approaches and new analogs. Mini Rev Med Chem 2006; 6:395-400.
7. Liang J, Huang M, Duan W, Yu XQ, Zhou S. Design of new oxazaphosphorine anticancer drugs. Curr Pharm Des 2007; 13:963-978. (Pubitemid 46628292)
8. Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin Drug Metab Toxicol 2010; 6:919-938.
9. Brock N. Oxazaphosphorine cytostatics: past-present-future - Seventh Cain Memorial Award lecture. Cancer Res 1989; 49:1-7. (Pubitemid 19024399)
10. Brock N, Pohl J. Development of oncological therapeutic agents: current state and outlook with special regard to the situation in Germany. Drug Res 2000; 50:946-953.
11. Holzgrabe U. Glufosfamide-A new N-lost derivative. Pharm Unserer Zeit 2006; 35:158-159.
12. ASTA Medica, Glufosfamide (investigator's brochure). Frankfurt, Germany, 1999.
13. Niculescu-Duvaz I. Glufosfamide (Baxter Oncology). Curr Opin Investig Drugs 2002; 3:1527-1532.
14. Adis International Limited. Glufosfamide: Beta-D-Glc-IPM, D-19575. Drugs R&D 2005; 6:49-52.
15. Engel J, Klenner T, Niemeyer U, Peter G, Pohl J, Schübler M, et al. Glufosfamide. Drug Future 2000; 25:791-794.
16. Jin S, Di Paola RS, Mathew R,White E. Metabolic catastrophe as a means to cancer cell death. J Cell Sci 2007; 120:379-383. (Pubitemid 46332501)
17. Sheng H, Niu B, Sun H. Metabolic targeting of cancers: from molecular mechanisms to therapeutic strategies. Curr Med Chem 2009; 16:1561-1587.
18. Seker H, Bertram B, Burkle A, Kaina B, Pohl J, Koepsell H, et al. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumor therapeutic agent. Br J Cancer 2000; 82:629-634. (Pubitemid 30085201)
19. Pohl J, Bertram B, Hilgard P, Nowrousian MR, Stuben J, Wiessler M. D-19575-a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother Pharmacol 1995; 35:364-370.
20. Veyhl M, Wagner K, Volk C, Gorboulev V, Baumgarten K, Weber WM, et al. Transport of new chemotherapeutic agent beta-Dglucosylisophosphoramide mustard (D-19575) into tumor cells mediated by Na+-D-glucose cotransporter SAAT1. Proc Natl Acad Sci U S A 1998; 95:2914-2919.
21. Kleta R, Burckhardt BC, Wolff NA, Schlatter E. Unexpected electrophysiological effects of D-19575, a new cytostatic drug. Nephrol Dial Transplant 1999; 14:18-20. (Pubitemid 29358850)
22. De Rouveze M-CA, Gilard V, Martino R, Malet-Martino M, Niemeyer U. Hydrolytic pathway of glufosfamide, a new phosphorylated anticancer agent. Phosph Sulf Silic Rel Elem 2002; 177:1735-1738.
23. Arafa HM. Possible contribution of b-glucosidase and caspases in the cytotoxicity of glufosfamide in colon cancer cells. Eur J Pharmacol 2009; 616:58-63.
24. Sun YM, Chen XY, Zhong DF. Identification of glufosfamide metabolites in rats. Yaoxue Xuebao 2006; 41:513-517.
25. Sun Y, Chen X, Xu H, Guan Z, Zhong D. Stability of glufosfamide in phosphate buffers and in biological samples. J Chromatogr B Analyst Technol Biomed Life Sci 2006; 832:224-230. (Pubitemid 43339950)
26. Kümmerer K, Al-Ahmad A, Bertram B, WieXler M. Biodegradability of antineoplastic compounds in screening tests: influence of glucosidation and of stereochemistry. Chemosphere 2000; 40:767-773. (Pubitemid 30085799)
27. Stuben J, Port R, Bertram B, Bollow U, Hull WE, Schaper M, et al. Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat. Cancer Chemother Pharmacol 1996; 38:355-365.
28. Chen X, Sun Y, Cao X, Jin F, Zhong D. Determination of glufosfamide in rat plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectr 2005; 19:1839-1843. (Pubitemid 40886709)
29. Styczyński J, Wysocki M, Débski R, Balwierz W, Rokicka-Milewska R, Matysiak M, et al. In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report. Acta Biochim Pol 2002; 49:221-225.
30. Styczyński J, Wysocki M, Kurylak A, Juraszewska E, Malinowska I, Stanczak E, et al. In vitro activity of glufosfamide in childhood acute leukemia. Anticancer Res 2002; 22:247-250.
31. Briasoulis E, Judson I, Pavlidis N, Beale P,Wanders J, Groot Y, et al. Phase I trial a 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J Clin Oncol 2000; 18:3535-3544.
32. Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Schö ffski P, et al. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer 2003; 39:2334-2340. (Pubitemid 37214857)
33. Van den Bent MJ, GrisoldW, Frappaz D, Stupp R, Desir JP, Lesimple T, et al. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 2003; 14:1732-1734. (Pubitemid 38029044)
34. Giaccone G, Smit EF, De Jonge M, Dansin E, Briasoulis E, Ardizzoni A, et al. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer: a phase II trial of the EORTC - New Drug Development Group. Eur J Cancer 2004; 40:667-672. (Pubitemid 38326615)
35. Chiorean EG, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, et al. A phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2008; 61:1019-1026. (Pubitemid 351423130)
36. Shimizu T, Okamoto I, Tamura K, Satoh T, Miyazaki M, Akashi Y, et al. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. Cancer Chemother Pharmacol 2010; 65:243-250.
37. Becker R, Ritter A, Eichhorn U, Lips J, Bertram B,Wiessler M, et al. Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by cytostatic drug beta-D-glucosyl-ifosfamide mustard. Br J Cancer 2002; 86:130-135. (Pubitemid 34146353)
38. Mazur L, Opydo-Chanek M, Stojak M, Baran J, Niemeyer U. Induction of DNA breakage in U937 cells by oxazaphosphorines. Folia biol (Kraków) 2010; 58:15-20.
39. Ammons WS, Wang JW, Yang Z, Tidmarsh GF, Hoffman RM. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia 2007; 9:625-633. (Pubitemid 47328081)
40. Mazur L, Opydo-Chanek M, Halicka HD, Dar(ynkiewicz Z, Niemeyer U. Induction of programmed cell death by glufosfamide. Cancer Therapeutics: The Road Ahead. Materials of Capri Science Conference. Capri, Italy, 2007. p. 52.
41. Mazur L, Opydo-Chanek M, Stojak M, Adamus M, Niemeyer U. Cell death - inducing potential of new generation oxazaphosphorines and antimetabolites. Materials of 16th Euroconference on Apoptosis. Bern, Switzerland, 2008. p. 107.
42. Opydo-Chanek M, Mazur L, Stojak M, Niemeyer U. Comparative effects of new generation oxazaphosphorines on cancer cell death. Materials of 6th Swiss Apoptosis Meeting. Bern, Switzerland, 2010. p. 46.
43. Mazur L, Stojak M, Opydo-Chanek M, Niemeyer U. Mitotic catastrophe induction in U937 cells by oxazaphosphorines. Acta Biol Cracov Ser Zool 2009; 51:17-22.
44. Mazur L. Indukowanie apoptozy i nekrozy komórek hematopoetycznych przez tiole, promieniowanie jonizujáce i zwiá zki chemioterapeutyczne (Induction of apoptosis and necrosis of hematopoietic cells by thiols, ionizing radiation and chemotherapeutic agents). Kraków: Ksiégarnia Akademicka; 2002.
45. Mazur L, Opydo-Chanek M, Niemeyer U. Frequency of micronuclei induced in the mouse erythropoietic system by new generation oxazaphosphorines. Acta Biol Cracov Ser Zool 2008; 50:5-10.
46. Ding YW, Li ZK, Zhao H, Zhang JX, Li BO. Toxicity of glufosfamide in Beagle dogs following intravenous injection. J Pharmacol Univ 2009; 40:535-538.
47. Tidmarsh GF, Kudajbergenova IO, Navrusov SN, Stepula VV. An open label phase II trial of glufosfamide: a b-D-glucose-linked isophosphoramide mustard given as 1-hour infusion in patients with advanced breast cancer. J Clin Oncol 2004; 22:646.
48. Bröker LE, Giaccone G. The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer 2002; 38: 2347-2361.
49. Chiorean EG, Dragovich T, Hamm J, Barrios CH, Gorini CF, Langmur VK, et al. A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-náve pancreatic adenocarcinoma. Am J Clin Oncol Cancer Clin Trial 2010; 32:111-116.
50. Anderson P, Aguilera D, Pearson M,Woo S. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control 2008; 15:38-46. (Pubitemid 351481990)
51. Dollner R, Dietz A, Kopun M, Helbig M, Wallner F, Granzow C. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent. Anticancer Res 2004; 24:2947-2951. (Pubitemid 39407171)
52. Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, et al. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer 2009; 45:1589-1596.
53. Lacombe D, Fumoleau P, Zwierzina H, Twelves C, Hakansson L, Jayson G, et al. The EORTC and drug development. Eur J Cancer 2002; 38:19-23.
54. Lacombe D, Butler-Smith A, Therasse P, Fumoleau P, Burtles S, Calvert H, et al. Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network. Cancer Invest 2003; 21:137-147. (Pubitemid 36292513)
55. Bayés M, Rabasseda X, Prous JR. Gateways to clinical trias. Methods Find Exp Clin Pharmacol 2003; 25:387-408.
56. Bayés M, Rabasseda X, Prous JR. Gateways to clinical trias. Methods Find Exp Clin Pharmacol 2004; 26:211-244.
57. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2008; 30:543-588.
58. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2009; 31:107-146.